Internship Offers experience Running Biotech Lab

Allison Darling ’26 poses in Phenomenex’s laboratory. The company is based in the Mansfield Bio-Incubator, a cooperative working space for science companies.

Allison Darling ’26, an aspiring doctor, gains valuable laboratory skills at Mansfield-based Phenomenex

Allison Darling is just beginning her Wheaton journey as a first-year student, but she already is gaining valuable laboratory skills that will give her an edge in a future career in medicine.

Since November 2022, Darling has served as an intern at Phenomenex, a California-based scientific company that has a laboratory in Mansfield, Mass. She has been learning essential aspects of running a lab: from managing inventory and safety procedures to gaining hands-on experience with techniques like instrumentation and initial calibration assays.

“So far, I have learned a lot about the machines in our lab and how they work; machines like mass spectrometers, HPLCs, NanoDrop Microvolume Spectrophotometers, pH meters and cell culture hoods. I also have gotten to lead several projects regarding inventory and organization,” said Darling, who is double majoring in neuroscience and French.

“As the lab sets up, I am organizing and categorizing, but I am really learning about what it means to be a scientist,” she said.

Darling’s placement at Phenomenex is part of a partnership between local biotech companies, including EverCell Bio, and Wheaton’s Biology Department and Social Entrepreneurship Program.

As the lab gets up and running, Darling will learn from Phenomenex’s scientists, who specialize in the characterization and separation of various biomolecules. The lab’s projects use cutting-edge technology to drive innovation in the drug discovery field.

Michael Mattera, LC/MS analyst at Phenomenex, said Darling has demonstrated adaptability as the startup establishes its laboratory. She works hard and has a good attitude, and isn’t afraid to ask questions to ensure her understanding of the work they do, he said.

Mattera added that many science students don’t have the opportunity to practice many laboratory skills until graduate school.

“The ability to walk into an interview and say, ‘I can use micropipettes and I’ve calibrated balances and pH meters’ will give you a leg up in job hunting as a recent graduate,” he said.

Darling calibrates a pH meter.

Darling’s placement at Phenomenex is part of a partnership between local biotech companies, including EverCell Bio, and Wheaton’s Biology Department and Social Entrepreneurship Program.

As the lab gets up and running, Darling will learn from Phenomenex’s scientists, who specialize in the characterization and separation of various biomolecules. The lab’s projects use cutting-edge technology to drive innovation in the drug discovery field.

Michael Mattera, LC/MS analyst at Phenomenex, said Darling has demonstrated adaptability as the startup establishes its laboratory. She works hard and has a good attitude, and isn’t afraid to ask questions to ensure her understanding of the work they do, he said.

Mattera added that many science students don’t have the opportunity to practice many laboratory skills until graduate school.

“The ability to walk into an interview and say, ‘I can use micropipettes and I’ve calibrated balances and pH meters’ will give you a leg up in job hunting as a recent graduate,” he said.

Michael Mattera, LC/MS analyst at Phenomenex (left), with Darling


Darling secured the internship by networking, she said. After she received an email last fall about an opening event for Mansfield Bio-Incubator, a collaborative space that includes Phenomenex and 24 other startups, she decided to attend, not knowing what to expect.

“That is where I met [Wheaton Professor of the Practice of Social Entrepreneurship] Pabel Delgado and the Phenomenex group. I wanted to be involved and I put myself out there, but truly I owe it to Pabel and his willingness to help everyone succeed,” she said.

The position fits well into Darling’s long-term goal of becoming a doctor. Her aspiration stems from personal experiences with neurological disorders.

“I have had three major concussions, been diagnosed with vestibular migraines, and have seen the clinical process through it all. Although, this time, I’d like to be on the other side of things,” she said. “In addition, my best friend was diagnosed with a brain tumor, and another friend had anxiety/depression—two very different things but both have to do with the brain. I see the brain as a puzzle and I want to help find solutions when things go wrong.”

Darling at entrance to Phenomenex lab

With her French major, Darling hopes to develop fluency in the language so she can someday pursue a career with Doctors Without Borders, or Médecins Sans Frontières, and provide medical treatment to those in impoverished and war-stricken countries.

Darling said the most meaningful part of the Phenomenex internship is knowing that she is starting to make that dream come true.

“I know that these are the first steps in my path to going to medical school, joining Doctors Without Borders, traveling the world, and doing all the things I love. That is the most gratifying part,” she said.

Mansfield Bio-Incubator is One Of The 13 Companies Named Winners Of Team Massachusetts ‘Impact’ Awards

Mar 1, 2023

For more information, please contact: Pete Abair, Executive Director 617-924-4600, pabair@massecon.com

13 GROWING MASSACHUSETTS FIRMS NAMED WINNERS OF Team Massachusetts ‘IMPACT’ AWARDS

WATERTOWN, MA – MassEcon, the state’s private sector partner in promoting business growth in Massachusetts, today announced its Nineteenth Annual Team Massachusetts Economic Impact Award, recognizing 13 companies for their outstanding contributions to the Massachusetts economy. The companies were selected on the basis of job growth, facility expansion and investment, community involvement, and commitment to diversity, inclusion, and equity initiatives since January 1, 2022.

The winners will be honored at a ceremony on April 6, 2023, at Gillette Stadium in Foxborough, with Citizens as presenting sponsor. In addition, Bristol Myers Squibb will receive the 2023 Massachusetts Summit Achievement Award. The winning companies (listed below) were selected after site visits and interviews with regional teams of judges. The company expansion projects represent a financial investment of over $966 million, more than 1.4 million square feet, and more than 1,500 jobs added to the state’s economy.

“A unique feature of these awards is the recognition of small employers alongside global companies,” stated Peter Abair, MassEcon’s executive director. “Each employer shares a commitment to Massachusetts and represents an economy that continues to innovate and grow.”

The Impact Awards this year will include a special award, the Massachusetts Summit Achievement Award, which recognizes an employer for its commitment over time to Massachusetts with multiple business expansions, investments in new employees, and commitment to the broader Massachusetts community. The inaugural award goes to Bristol Myers Squibb. In 2007, BMS won a Massachusetts Economic Impact Award, recognizing its initial facility investment at Devens. In 2016, BMS won an additional Gold Impact Award for its expansion. In 2023, BMS would have been in the position of being recognized for its two expansions completed in 2022 at Devens and Cambridge.

“We are honored to receive the Massachusetts Summit Achievement Award from MassEcon recognizing Bristol Myers Squibb’s continued investment in Massachusetts,” said Odile Smith, vice president and head of the Devens site. “2023 is a big year for us with the expansion of our cell therapy operations in Devens and the opening of a brand new R&D facility in Cambridge. The life sciences industry is thriving across the commonwealth, and we truly love being a part of the community as we transform patients’ lives every day through science.”

“Congratulations to all the winners, who have positively impacted our state through job creation, facility investment and community involvement,” said Lisa Murray, President, Citizens, Massachusetts. “We at Citizens share in your commitment to strengthening communities through hard work and innovation, which is critical to ensuring that we meet the accelerating needs of the economy.” One awardee, Monogram Foods, will be the first honoree in the history of the Awards to receive recognition for investments in two different regions, with its recent growth in Haverhill and Medford. 1

19TH ANNUAL TEAM MASSACHUSETTS ECONOMIC IMPACT AWARD WINNERS -

Read about each of the companies here: company descriptions

ABOUT MassEcon

MassEcon’s mission is to promote and champion Massachusetts as the best place to start, grow and locate a business. Built upon a robust network of corporate and civic members, MassEcon convenes public and private sector leaders of industry to create an inclusive business ecosystem that enhances job growth across a diverse talent pool; promotes investment in all communities; expands equitable opportunities throughout the Commonwealth. www.massecon.com.

ABOUT TEAM MASSACHUSETTS

Team Massachusetts is the informal name given to a consortium of state and quasi-public economic development agencies, such as MassDevelopment, Mass Office of Business Development, MOITI, and the Mass Life Sciences Center, as well as private sector organizations focused on economic development in Massachusetts, such as MassEcon, MassBio, and MassMedic.

ABOUT Citizens Financial Group, Inc.

Citizens Financial Group, Inc. is one of the nation’s oldest and largest financial institutions, with $162.7 billion in assets as of June 30, 2019. Headquartered in Providence, Rhode Island, Citizens offers a broad range of retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations and institutions. Citizens helps its customers reach their potential by listening to them and by understanding their needs in order to offer tailored advice, ideas and solutions. In Consumer Banking, Citizens provides an integrated experience that includes mobile and online banking, a 24/7 customer contact center and the convenience of approximately 2,900 ATMs and approximately 1,100 branches in 11 states in the New England, Mid-Atlantic and Midwest regions. Consumer Banking products and services include a full range of banking, lending, savings, wealth management and small business offerings. In Commercial Banking, Citizens offers corporate, institutional and not-for-profit clients a full range of wholesale banking products and services, including lending and deposits, capital markets, treasury services, foreign exchange and interest rate products, and asset finance.

More information is available at www.citizensbank.com or visit us on Twitter, LinkedIn or Facebook.

Company Spotlight: Aclarity Is Expanding Its Laboratory Operations At Mansfield Bio-Incubator

Mansfield Bio-Incubator is proud to announce the expansion of the laboratory operations of Aclarity, a cleantech company specializing in destruction of Per- and Polyfluorinated Alkylated Substances (PFAS) also known as “forever chemicals”. The company will occupy a first-class 700 square feet private laboratory suite in our facility. 

PFAS are incredibly harmful to human health and persistent in the environment. They build up in the food we eat and the water we drink. PFAS is toxic to humans, leading to health problems such as cancer and fertility issues. Yet, PFAS is ubiquitous. We must urgently destroy PFAS from our planet. But current practices to remove PFAS from the environment are not fit for purpose. The typical process involves using an incinerator to break down PFAS, but that is energy-intensive and can still release harmful chemicals into the environment. Instead, Aclarity provides a sustainable way to destroy PFAS forever. Aclarity develops and deploys electrochemical water treatment systems that cost-effectively destroy PFAS in wastewater and liquid waste streams. They save customers money, time, operational complexity and reduce their liabilities. By permanently destroying PFAS, Aclarity is repairing our environment and ensuring cleaner, safer water for all. 

Just last month, Aclarity announced that it has successfully destroyed PFAS chemicals at a customer’s site, at volume, in landfill leachate, a primary source of PFAS contamination in the environment. Third party lab results confirmed continuous destruction of up to 99% of PFOS in landfill leachate, bringing levels to below detection limits. The full-scale pilot, sponsored by Xylem, a leading water technology company, demonstrates that PFAS can be destroyed at full-scale capacity for large operations. The modular nature of the Aclarity technology allows for destruction of low volume streams and even those requiring upwards of millions of gallons per day to be treated. 

After a recent fundraise of over $3 million, Aclarity is deploying the technology across the country. The company is currently planning several permanent installations in 2023 and is evaluating strategic partners to expand into verticals such as drinking water and groundwater remediation. 

With these ambitious plans, Aclarity has to be cognizant of the footprint it needs to be able to accomplish the goals. “Aclarity’s rapid growth and opportunity to be in proximity to the top-notch talent in the Boston Area requires us to think on our feet and be flexible. Mansfield Bio-Incubator’s location and lab space has been extremely useful to our team. Their willingness and ability to accommodate our changing needs as well as networking opportunities provided has been tremendously helpful in our growth and the development of our PFAS destruction technology,” said Julie Bliss Mullen, Aclarity’s Chief Executive Officer. 

For more information, please visit their website at https://www.aclaritywater.com/. 

Mansfield Bio-Incubator is fully committed to fostering the development of the ground-breaking technologies like Aclarity’s PFAS elimination from our water supply. Our diverse community is accepting applications to become our members. For more information, please visit us at https://www.bioinc.org 

 

Glass Bottle Factory Finds New Life as Biotech Space

The lab facility helps grow the thriving biotech community in Southeastern Massachusetts

Nov 18, 2022 | 3 min read | MaryBeth DiDonna

PDF Version

The Mansfield Bio-Incubator in Mansfield, MA, was completed in February 2022. At a cost of $4 million, the facility measures 26,000 sq. ft. in total, with 16,000 sq. ft. of Phase II buildout. CannonDesign served as architect on the project, while NV5 provided engineering services and Timberline Construction did the buildout. 

Lab facility in the Mansfield Bio-Incubator

COPYRIGHT © 2022 MANSFIELD BIO-INCUBATOR, INC. ALL RIGHTS RESERVED

Lab Manager spoke to Alex Margulis, Chief Operating Officer at Mansfield Bio-Incubator, about this facility’s interesting history and its outlook for the future. 

Q: What was the need for this facility? Is it replacing an outdated existing facility or accommodating new research/ a new program? 

A: Mansfield Bio-Incubator is located on a 64-acre property formerly built as a glass bottle factory in the 1970s. In the 1980s, the factory closed down and the facility was used as a transportation/warehousing hub. However, the location and the layout of the property is better suited for a biotech due to the proximity to Boston/Cambridge as well as two other major research clusters in New England in Worcester and Providence. Recognizing this, previous property owners generously donated $2 million to build the initial 10,000 square feet facility in 2017. The footprint consists of shared and private laboratory and office space to encourage the collaboration and to nucleate a biotech mini-cluster in Southeastern Massachusetts, to relieve the congestion and high prices in Boston and Cambridge and therefore help sustain the state’s coveted number one spot in the world in biotech. Within two to three years, the demand started to outgrow the physical footprint. 

To continue growing the biotech community in the region, we have partnered with Massachusetts Life Science Center, a state agency dedicated to growing Life Sciences in Massachusetts, and a private foundation, to build a Phase II expansion. The Phase II expansion is an extension of our original footprint built out in 2017. It was built to attract high-quality startups who desire a top-notch BSL-2 space and grow the biotech cluster in Southeastern Massachusetts. Our long-term aim is to create a campus where both earlier-stage and later-stage companies learn from each other. In particular, this is an ideal spot for a late-stage company to build a manufacturing facility.

Q: What kinds of sustainability initiatives have been included in the design plan? Is the facility pursuing LEED certification or something similar? 

A: The key elements in the design plan were high-quality insulation and the option to vary the air exchange rate within an individual suite (private suites of 325, 675, and 2,700 square feet). Finally, 50 percent of the electricity is generated from the solar farm nearby. We would consider pursuing a LEED certification.

Q: Is there anything particularly unique or groundbreaking about your facility or the design plan?

A: We sought to combine the highest quality standard for the laboratory while at the same time providing an open space that inspires collaboration and flexibility to adapt to each start-up’s ever-changing individual needs. With a 21st century dubbed as a biotech era, more and more applications of biotechnology will require strict engineering controls to ensure safe environment and eliminate any cross-contamination between the different enclosed (private) spaces. A robust air exchange within a shared space is also critical to minimize the chance of cross-contamination. The design of the facility aims to address this critical aspect of R&D.

Q: What sorts of challenges did you encounter during the design/build process, and how did you overcome them? 

A: From construction during COVID, to disruptions in the supply chain, to the transition in ownership and the need to overcome existing building restrictions and limitations, we faced several obstacles in the process of turning this dream into a reality. We overcame these challenges through grit, perseverance, and the collective help from our architects, engineering design, and construction firms.

Q: If a similar facility or program were to look at your lab for inspiration, what do you think they will take away as an example of what they should also implement in their own lab?

A: One piece of advice I’d share: You should seek to ensure the infrastructure is as flexible as possible with minimal fixed casework and ample room to add more electrical power and HVAC capabilities, as each startup has unique needs and even a later stage company’s priorities shift rapidly. Most importantly, the HVAC design must ensure no cross-contamination since very often the R&D work requires the use of air-borne pathogens such as bacteria, viruses, or parasites.

Mansfield Bio-Incubator Unveils Expanded Lab Campus

With 26,000 total square feet of lab space, the expansion cements the non-profit incubator as one of the largest collaborative life sciences spaces in Massachusetts’s booming biotech ecosystem.




MANSFIELD, MA, October 25, 2022 – Mansfield Bio-Incubator, a non-profit organization dedicated to providing life science innovators with affordable laboratory space, announced today the opening of its newest and largest facility, Southeastern Massachusetts’ Campus for Life Science Innovation and Innovators.

 

Community leaders, investors, and technology providers gathered at the Mansfield site on Wednesday, October 19, for a ribbon-cutting ceremony, networking, and presentations from the groundbreaking start-ups the incubator will host.

 

This latest expansion triples the non-profit’s laboratory footprint, offering state-of-the art shared and private BSL2+ laboratories to life sciences and biotech start-ups at all stages of development. The Mansfield Bio-Incubator provides founders and their teams with critical R&D and production support, enabling them to further their innovative research and development while attracting early-stage funding from investors and venture capital. The non-profit further fosters accelerated growth through academic-style collaboration and business support, allowing incubator start-ups to better fund and scale its operations.

 

“Mansfield Bio-Incubator is one of the fastest-growing life sciences laboratory campuses in the Boston-Providence innovation corridor and we’re elated to kindle up the next phase in our expansion,” remarked Russ Yukhananov, PhD, President of BioInc. “The unique conceptual design with emphasis on open space stimulates the exchange of ideas and creativity and promises to be a lasting contribution to our region’s leadership in life sciences and an investment in the future of so many innovators.”

 

“Mansfield Bio-Incubator’s newest facility expands our total laboratory space by 10,000 square feet,” Chief Operating Officer Alex Margulis said. “This means more space for new start-ups, new technologies, new collaborations, and more room for groundbreaking research and development in some of the most promising areas of life sciences—from opioid deterrence to breast cancer, to sustainable biomaterials and more.”

 

“A key differentiator of the Mansfield-Bio Incubator is the powerful relationships that form between supporters and start-ups,” Phenomenex President Matthew Turner said. “We have the opportunity to work within this innovative ecosystem to push our technology to the next level—and this helps us better support our customers who are working on some of the world’s toughest problems. We’re happy to have a presence in this community and look forward to continuing to build strong relationships.”

 

The grand opening coincides with the opening of a 700 square feet laboratory suite by Phenomenex—its first formal lab presence on the East Coast. Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, governmental and academic laboratories.

 

The Phenomenex laboratory is comprised of cutting-edge analytical instruments such as mass spectrometers, UHPLC, and sample preparation tools and technologies. The high-end equipment will be available to member companies and will be staffed by Phenomenex’s biopharma experts, serving as an indispensable suite for current and future start-ups.

 

The celebration featured remarks from leaders and experts, including:

-       Russ Yukhananov, PhD, President, and Alex Margulis, PhD, COO, Mansfield Bio-Incubator

-       Matt Turner, President, Phenomenex

-       Jake Auchincloss, Massachusetts Representative

-       Margaret LaForest, Boston Regional Director at MA Office of Business Development at Commonwealth of Massachusetts

-       Paul Feeney, Massachusetts State Senator

-       Ben Bradford, Vice President of Economic Development and Workforce, Massachusetts Biotechnology Council

-       Kenn Turner, President and CEO, Massachusetts Life Sciences Center

-       Kevin Dumas, Town Manager, Town of Mansfield, MA

-       Imran Chowdhury, PhD, Diana Davis Spencer Chair of Social Entrepreneurship, Wheaton College

 

Alongside Phenomenex, presenting companies included:

-       Hilltop Bio is a veterinary biotech company developing innovative regenerative therapies focused on helping our four-legged friends reduce inflammation from injuries or disease.

-       3Daughters is a Women’s Healthcare Company developing a new evolutionary intrauterine device (IUD) for contraception, based on physics, that conforms to a woman’s body.

-       Beyond Biotech provides rAAV-related services to biological and medical researchers in universities, institutes, hospitals and biopharmaceutical companies.

-       Entrinsic Bioscience leverages proprietary biomapping and electrophysiology platform to identify, target and validate combinations of amino acids as functional ingredients and APIs that deliver highly specific, efficient, and life enhancing health benefits.

-       Emitech is developing a wearable bracelet for real-time and reliable narcotic detection that offers wireless communication with a user interface (smartphone, computer), with multiple sensors in the array to test for many narcotics (mostly synthetic).

-       Oncovolution is developing a new generation of platinum-based chemotherapies designed to increase tolerable dosages for patients.

-       Therabene is developing highly targeted PROTAC molecules to attack cancers, as well as viral and autoimmune diseases.

-       Eighty-Eight Pharma, Inc. is developing two pipeline medical products, the Oppotoxy™ Bottle and the CAREspace Container. Eighty-Eight is also looking for a marketing partner for the Tuttle Safe™.

-       UpLevel Foods produces condiments that contain the most optimal nutrient density, and that’s important for the health and vitality of you and your family.

-       Turtle Health is bringing fertility care to your doorstep. They are developing the most accurate at-home fertility testing options to provide you with personalized, medically meaningful information to help you plan and manage your fertility journey, early and affordably.

 

About Mansfield Bio-Incubator

Mansfield Bio-Incubator is a non-profit organization whose mission is to facilitate and assist the creation, growth, and success of the next generation of biotech companies. Our incubator assists these companies and nurtures entrepreneurial and economic development in the community by maintaining affordable lab and office space to lease, services, training, mentoring, and a network of professional advisors. We provide entrepreneurs, innovative life-sciences start-ups, students, and faculty of Massachusetts colleges and vocational schools with the lab space to rent and resources they need to test out, challenge, and nurture early ideas and will teach students the skills for a successful career in the biotech industry.





This Startup Is Turning a Horse IUD into More Painless Birth Control for Humans.

3Daughters wants to replace the traditional T-shaped IUD with its own IUD made of three, tiny elliptical units with a magnetic core that is covered in polymer and then coated in copper.

3Daughters

By Hannah Green - Inno Reporter

October 25, 2022, 11:00am EDT

A new startup is aiming to use a new technology—first developed for use in horses—to create a more painless intrauterine device.

IUDs are one of the most effective forms of birth control, but the insertion and removal process can be painful. 3Daughters wants to replace the outdated, T-shaped IUDs with its new magnetic, frameless IUD. This month, the startup closed an early-stage round of just over $1 million to push its work forward. 

Typically to insert an IUD, a doctor starts by using a sounder, a rod with measurement markers on it, to find the top of the uterus. This is where the T-shaped device must be placed. 3Daughters co-founder Mary Beth Cicero said the sounder and the IUD hitting the top of the uterus is often one of the worst pain points in this process.

3Daughters’ IUD is made of three, tiny elliptical units with a magnetic core that is covered in polymer and then coated in copper, said co-founder Shelley Amster. The three units are fed single file through an inserter into the uterus where they form a triangle shape. The IUD floats in the lower quadrant of the uterus. A magnetic retriever is used for removal. This eliminates the need to use a sounder and push on the top of the uterus, Amster said.

This new IUD technology was invented by Carlos Gradil, a veterinarian and professor of veterinary and animal science at UMass Amherst. Gradil first created this IUD for use in horses.

“He had really tested it, proven the safety and efficacy in horses, and has published on it,” Cicero said. “And he didn’t really understand the human market. And that’s where Shelley came in.”

Amster is one of the founding board members of the Mansfield Bio-Incubator and an original organizer of the Massachusetts Life Sciences Innovation (MALSI) Day. Amster said she came in with a diligence team to vet Gradil’s work and determine if it could be translated to human use. She brought in Cicero, a pharma executive with experience in business development marketing, and the pair approached Gradil about commercializing the technology in humans.

Mary Beth and I basically told UMass and Carlos that if we could get some translation grants to prove…and develop a prototype, we would license the technology and form a corporation,” Amster said.

That was about a year ago. With six grants now under their belt, the co-founders spent the last year developing prototypes of the IUD and the glider for insertion and retrieval and meeting with the FDA to map out the clinical path forward.

The co-founders have also brought on board a team of advisors, including Dr. David Archer, director of clinical research for the Contraceptive Research and Development Program; Dr. Mary Lake Polan, professor and Ob/Gyn Yale University School of Medicine; and Dr. Tara Kumaraswami, director of the Ob/Gyn residency program at UMass Medical School. 

“We have people that are key opinion leaders of key opinion leaders,” Amster said.

Amster said they were able to land these advisers because she and Cicero have been working in the field of women’s health innovation for decades. Amster and Cicero said they considered starting 3Daughters a full circle moment in their careers. Amster started working in a preterm clinic working in infertility. Cicero headed up U.S. marketing at Serono when the company focused on infertility before starting her own consulting practice and working with many women’s health companies.

Cicero said the company plans to use its new capital to finalize the prototype design, transfer it to manufacturing, and begin preclinical work. They also plan to file new IP under the 3Daughters name. The U.S. and European patents for the technology are licensed from UMass Amherst, Cicero said.

Their goal is to file an IND by the end of next year. The startup also expects to raise a $10 million round next year to propel it through its Phase 1 feasibility study in 2024. After that, Cicero said 3Daughters would look for a commercialization partner to help them break into this industry.

Member Company Spotlight: AOA Dx is Aiming to Detect Ovarian Cancers Sooner.


AOA Dx Inc has partnered with a leading researcher at McGill University to develop the first early stage ovarian cancer liquid biopsy diagnostic test. The co-founders have worked together at two previous startups in the women’s health space, both resulting in successful exits upon commercialization. Ovarian cancer is the deadliest gynecological disease because there is no accurate testing method and therefore its symptoms are continuously mistaken for benign conditions, making it incredibly difficult to diagnose the disease in the early stages. The team has previously raised a $7M Seed round and completed a 400+ retrospective patient study showing excellent sensitivity and specificity. Ovarian cancer is just the beginning. AOA has a platform of novel ganglioside tumor markers to disrupt early cancer detection. AOA Dx is currently developing their assay and conducting further clinical studies.

Recently, Oriana Papin-Zohgbi, the company’s Co-founder and CEO, met with Mansfield Bio-Incubator’s Advisory Board as part of the routine check-in with the member companies. “I had a great meeting with our Advisory Board at Mansfield Bio-Incubator to brainstorm fundraising strategy and growing our company! Excited to continue working with this team.”

Mansfield Bio-Incubator is excited to have AOA Dx as our member company and is committed to supporting their work to ensure their success. They are currently hiring a Director of Clinical Operations: https://www.aoadx.com/clinical-director-operations.

For more information, visit their website at https://www.aoadx.com/.

Member Company Spotlight: Omnigen is Taking Her First steps into the United States

Omnigen as a member of the Mansfield Bio-Incubator in Boston

In the beginning of February, Omnigen went on a mission to Boston for the SLAS2022 International Conference and Exhibition, organised and financed by DIGI-B-CUBE. During this mission, Omnigen and Mansfield Bio-Incubator crossed paths, and it turned out to be a great match. In this interview, one of the co-founders of Mansfield Bio-Incubator, Alexander Margulis, tells us why that is the case.

Hi Alexander, nice to meet you! Can you tell us more about your educational background?

“Hi! So, my name is Alexander Margulis, and I have a PhD in Biochemistry and Molecular Biology from Stony Brook University in New York. My PhD project focused on the role of cell cohesion on cancer progression using three-dimensional models. After receiving my doctorate, I continued to work with similar models as a postdoctoral researcher at what is now Pfizer. What followed was a position at Genzyme, where I focussed on cell-based assays. It was not until later in my scientific career that I contributed to other life science companies with my knowledge. After my time at Genzyme, I set up laboratories for a biotech start-up called Bioarray Genetics, who were developing a test to stratify breast cancer patients in terms of response to chemotherapy.”

You have quite some impressive experiences under your belt. How did you end up co-founding the Mansfield Bio-incubator?

“Well, it began with some of the feedback I received from one of my supervisors back in the day. She felt that, with the personality I have and the skills I possess, you would be great at building something from scratch. So, at the age of forty, I decided to take this feedback and jump into a new opportunity to build a life science ecosystem in this region. In 2017, Mansfield Bio-Incubator opened the initial lab space, thanks to a generosity of private donors, and then secured money from Massachusetts Life Science Center to facilitate the expansion, right before the pandemic in 2020. Despite some delays due to the pandemic, we are now finally operational as of the end of February. We are filling up, and are, of course, always trying to attract new exciting companies from anywhere in the world. For this reason, I was really glad that the Netherlands mission in Boston brought exciting life science companies into our space, including Omnigen.”

 

“It becomes more paramount to connect companies like Omnigen to the Massachusetts network”

 

You have certainly come a long way since 2017. Can you tell us more about the mission that the incubator holds?

“Basically, our mission is to provide assistance to companies that make ground-breaking diagnostic therapeutics and other life science products. Besides that, we want to grow the entrepreneurial economy of this part of Massachusetts. The way our economy is currently developing is, also partly due to our geography, not sustainable. Obviously, Boston Cambridge is at the centre of the world in terms of biotech. But what people fail to understand is that the prices and real estate are exorbitant, and the commute is a nightmare. So, it becomes more paramount to connect companies like Omnigen to the Massachusetts network, and to provide them with options outside of Boston Cambridge. And that is what we are about.”

Why do you think a company such as Omnigen is suitable to connect to the Massachusetts network your incubator has?

“In my opinion, Omnigen is a great fit, because like our other incubator companies, Omnigen works in a variety of disciplines, from cancer diagnostic therapeutics to DNA-tests for horses. I am very impressed given the fact that Omnigen has a relatively small team with a big portfolio of products. I sincerely hope that we can help Omnigen in any way we can.”

 

“It is about what the company really needs. The opportunities are plentiful.”

 

Talking about offering help, what are the precise services and support you can offer life science companies such as Omnigen?

“Firstly, we will ask any company who becomes a member at our incubator to fill out a questionnaire, and then connect them to the advisory board. The advisory board will give the companies tailored advice based on the questionnaire and will involve the right people from the network to get the companies what they need. This can vary from funding opportunities to networking events, from accelerator programs to mentors, and from seminars to intern recruitment. In other words, it is about what the company really needs. The opportunities are plentiful.”

Plentiful indeed! So how do you think the incubator can add value specifically to European life sciences companies entering the United States market?

“We have a range of memberships, starting with the virtual basic business membership that Omnigen has. This membership includes basic analysis, connections to mentors for appropriate guidance and providing any connections necessary to expand into the United States market. When enough money is raised, Omnigen can rent a bench in our shared space. When that is the case, regional officials can add more capacity to let Omnigen grow right in this region of Massachusetts. In this way, we have a virtuous cycle. By providing an additional, affordable option to get your life science venture started, we keep Massachusetts as the number one biotech economy in the world, while European companies such as Omnigen can add more value to this economy and to the well-being of our country by providing products such as their Pancreatic Insightful Treatment Analysis platform.”

To end on a different note, would you recommend anyone to visit Boston?

“Absolutely, I cannot imagine living anywhere else at this point. There is no amount of money that can lure me to live in another place. We have a variety of spectacular nature within two hours of the city, including beaches and mountains. Boston has lots of great cultural events, and the city has a very passionate sports fan base. And I am not even talking about American football, but regular football. Also, I would argue that, for people from Europe, Boston would be the least of a culture shock. It is one of the most compact American cities, although probably not as compact as the Netherlands.”

Do you want to know more about the Mansfield Bio-Incubator? Visit their website here.

Original Source: https://business.omnigen.nl/en/portfolio/omnigen-is-taking-her-first-steps-into-the-united-states-2/

Company Spotlights: Turtle Health and Beyond Biotech are the First Two Companies in the New Laboratory Space at Mansfield Bio-Incubator

On March 1, 2022, Mansfield Bio-Incubator’s new 15,000 sqft space welcomed the first two new member companies.

Turtle Health is a women-led, Boston-based start up building a clinical platform to care for women and couples in the home. The company is working on a suite of devices, diagnostics, and technology that allow doctors to confidently care for patients via telemedicine, including remote pelvic ultrasound.

The woman-led founding team is bring a depth of healthcare experience – including previous leadership roles at Sanofi, Pfizer, Evolent, McKinsey, and Blue Cross Blue Shield – as well as a passion for patient care.

Turtle Health’s team has run three successful pivotal trials that generated a number of publications, most recently a paper in Obstetrics & Gynecology (‘the Green Journal’) comparing the performance of its ultrasound device to existing in-clinic imaging. Turtle Health is hiring a Warehouse & Laboratory Operations Manager. For more information, please click here.

Beyond Biotech provides rAAV-related services and products to biological and medical researchers in the universities and biopharmaceutical companies. Our service includes rAAV vector construction/quality control, shRNA and artificial miRNA design/construction/assay, rAAV packaging, and cell-based assay for gene therapy researches.

Traditional methods of rAAV particle manufacture are time and labor-consuming process with challenge of techniques and expensive equipment. Recent rise of investments in rAAV drug development and commercialization urges plenty of researches and pre-clinical trials to use rAAV as gene delivery vehicle, which requires large quantity and high purity rAAV particles. Beyond Biotech are dedicated to employ novel and standardized protocols to produce rAAV with helper-free system in HEK293 cells, which can decrease turn-around time and the cost of rAAV manufacture.

Since the high technical procedures of rAAV design/production/quality control requires extensive cost and time for rAAV platform development, we are dedicated to develop ready-to-use rAAV packaging kits with step-by-step protocols to produce high-purity rAAV particles, which would benefit junior faculties and scientists in scientific community who work in the gene therapy field with limited funding and technical resources.

Currently, Beyond Biotech are in the early phase of R&D, in order to scale-up our manufacture, we are actively looking for funding, collaboration and investment. Please find the detailed information in our website, www.biotechbeyond.com